# MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Source: https://onco.cc/trials/nct06534437/  
OnCo record `nct06534437` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of MEN1703, Glofitamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Ryvu Therapeutics SA, now recruiting.

## Summary

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) is a phase 2 interventional study registered as NCT06534437 by Ryvu Therapeutics SA, with 178 participants planned, started 2024-12-05 and due to reach its primary completion in 2026-12. Interventions recorded: MEN1703, Glofitamab. Conditions listed: Non-Hodgkin Lymphoma, B-cell. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06534437
- Phase: 2
- Setting: An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
- Sponsor: Ryvu Therapeutics SA
- Enrolled: 178

## Sources

- ClinicalTrials.gov NCT06534437: https://clinicaltrials.gov/study/NCT06534437

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Glofitamab](https://onco.cc/drugs/glofitamab/), [MEN1703](https://onco.cc/drugs/men1703/)
- companies: [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06534437.json